-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on OnKure Therapeutics, Lowers Price Target to $14

Benzinga·08/14/2026 17:15:26
语音播报
Oppenheimer analyst Leland Gershell reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Outperform and lowers the price target from $30 to $14.